Trial Profile
A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Sep 2018
Price :
$35
*
At a glance
- Drugs Ezetimibe/rosuvastatin (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Ildong Pharmaceutical
- 04 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.
- 04 Sep 2018 New trial record